Alnylam Pharmaceuticals Inc

Strong Financial Performance: Alnylam Pharmaceuticals reported Q1 2025 net product revenues of $469 million, representing a 28% year-over-year growth. The TTR franchise delivered $359 million in global net revenues, marking a 36% increase compared to Q1 2024. This growth reflects robust demand, particularly from the hereditary polyneuropathy market, with a 45% increase in U.S. sales.

Successful AMVUTTRA Launch: The FDA approved AMVUTTRA for ATTR cardiomyopathy in March 2025, with initial uptake showing strong momentum. Over half of targeted health systems included AMVUTTRA in their formulary within four weeks of approval, facilitating access for patients. Early engagement reflects broad usage among both experienced and new prescribers, indicating positive reception in the market.

Guidance Reiteration: Alnylam reiterated its guidance for the year, aiming for sustainable non-GAAP profitability in 2025. The company projects overall growth of 36% in the TTR franchise revenue, emphasizing confidence in the potential of AMVUTTRA and the continued growth of its existing product line.